Search clinical trials for: Ruxolitinib Phosphate
Total 3986 results
-
Washington University School of MedicineRigel PharmaceuticalsTerminatedMyelofibrosis | ThrombocytopeniaUnited States
-
Ascentage Pharma Group Inc.WithdrawnMyelofibrosisUnited States
-
Prisma Health-UpstateCompletedCOVID19 | Cytokine Release SyndromeUnited States
-
Hoffmann-La RocheCompletedMyelofibrosisItaly, United States, Canada, Germany
-
Sunnybrook Health Sciences CentreNovartisUnknownLeukemia, Lymphocytic, Chronic, B-CellCanada
-
Assistance Publique Hopitaux De MarseilleUnknown
-
Kartos Therapeutics, Inc.RecruitingMyelofibrosisUnited States, France, Australia, Spain, Germany, Bulgaria, Israel, Italy, Poland
-
The First Affiliated Hospital of Soochow UniversityUnknownSafety and EfficacyChina
-
University of CologneCompletedRecurrent Classical Hodgkin LymphomaGermany
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingHemophagocytic Syndromes
-
Institute of Hematology & Blood Diseases HospitalRecruitingTransplant-Related DisorderChina
-
Institute of Hematology & Blood Diseases HospitalRecruitingTransplant-Related DisorderChina
-
Karyopharm Therapeutics IncRecruitingMyelofibrosisUnited States, Korea, Republic of, Belgium, Italy, Spain, France, United Kingdom, Israel, Czechia, Taiwan, Canada, Germany, Romania, Bulgaria, Poland, Denmark
-
Incyte CorporationCompletedAtopic DermatitisUnited States, Canada
-
Incyte CorporationTerminatedMPN (Myeloproliferative Neoplasms)United States
-
XenikosNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsTerminatedSteroid-Refractory Acute Graft Versus Host DiseaseUnited States, Belgium, Croatia, France, Germany, Italy, Netherlands, Spain, United Kingdom
-
Novartis PharmaceuticalsCompletedMyelofibrosisFrance, United Kingdom, Belgium, Germany, Netherlands, Italy, Austria, Spain, Sweden
-
Novartis PharmaceuticalsCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingPrimary Myelofibrosis | Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Myelofibrosis Transformation in Essential ThrombocythemiaUnited States
-
French Innovative Leukemia OrganisationCompleted
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingKohlmeier Degos Disease With Neurologic InvolvementUnited States
-
University of NebraskaCompletedGraft-versus-host-disease (GVHD)United States
-
Gilead SciencesCompleted
-
Washington University School of MedicineIncyte CorporationWithdrawnCOVID-19
-
Bristol-Myers SquibbActive, not recruitingMyelofibrosisItaly, Spain, United States, Australia, France, Germany, Greece, Hungary, Israel, Korea, Republic of, Poland, Romania
-
Incyte CorporationActive, not recruitingPrimary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera MyelofibrosisUnited States, Spain, United Kingdom, Korea, Republic of, Belgium, France, Israel, China, Japan, Italy, Germany, Taiwan, Poland, Austria, Finland, Hungary, Norway, Romania, Turkey
-
Incyte CorporationCompletedHidradenitis SuppurativaUnited States, Canada
-
Incyte CorporationCompletedLichen SclerosusUnited States, Canada
-
Novartis PharmaceuticalsCompletedAcute Graft Versus Host DiseaseBelgium, Japan, Spain, France, Korea, Republic of, Canada, Italy, Denmark
-
National Cancer Institute (NCI)TerminatedLeukemia, Adult T-Cell | T Cell Leukemia, Adult | T Cell Leukemia, HTLV I AssociatedUnited States
-
Incyte CorporationCompletedMPN (Myeloproliferative Neoplasms)United States, Netherlands, Austria
-
Incyte CorporationTerminatedProstate CancerUnited States
-
Incyte CorporationCompletedAtopic DermatitisUnited States, Canada
-
Institute of Hematology & Blood Diseases HospitalNot yet recruitingThe Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA
-
Novartis PharmaceuticalsCompletedPrimary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisGermany
-
Incyte CorporationNovartisCompletedMyelofibrosisFrance, United Kingdom, China, United States, Netherlands, Germany, Italy, Austria
-
Novartis PharmaceuticalsCompletedAsian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MFPrimary Myelofibrosis (MF) | Post-Polycythemia Vera (PV) MF | Post-Essential Thrombocythemia (ET) MFTaiwan, Japan, Korea, Republic of, China
-
Incyte CorporationActive, not recruitingPrimary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera MyelofibrosisUnited States, Spain, United Kingdom, Korea, Republic of, China, Japan, France, Turkey, Germany, Israel, Poland, Belgium, Italy, Austria, Denmark, Finland, Norway
-
Novartis PharmaceuticalsCompleted
-
Incyte CorporationCompletedCutaneous Lichen PlanusUnited States, Canada
-
H. Lee Moffitt Cancer Center and Research InstituteIncyte CorporationCompletedMyelomonocytic LeukemiaUnited States
-
Novartis PharmaceuticalsCompletedMyelofibrosisUnited Kingdom, Germany, Canada, Singapore, Netherlands, Italy, Australia, France
-
M.D. Anderson Cancer CenterHelsinn Healthcare SACompletedMyeloproliferative DiseasesUnited States
-
Incyte CorporationRecruitingPregnancy Related | Atopic DermatitisUnited States
-
Baylor Research InstituteNot yet recruitingBreast Cancer | Metastatic Triple-Negative Breast CarcinomaUnited States
-
Constellation PharmaceuticalsActive, not recruitingPrimary Myelofibrosis | Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisKorea, Republic of, Spain, United States, Canada, Taiwan, Czechia, United Kingdom, Australia, Italy, Belgium, Germany, France, Israel, Greece, Malaysia, Netherlands, Austria, Turkey, Poland, Thailand, Hong Kong, Hungary
-
St. Petersburg State Pavlov Medical UniversityMinistry of Health, Russian FederationCompleted
-
Incyte CorporationCompletedMPN (Myeloproliferative Neoplasms)United States, Canada, Australia